Pablo Tebas News Today

An honest repairman. Water aerobics. Lifesaving medicine. These are just a few of the things New York Times readers are grateful for this year.

PHILADELPHIA — (July 7, 2022) — Under a Defense Advanced Research Projects Agency ( DARPA ) and Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense ( JPEO - CBRND ) funded program, a novel COVID -19 antibody delivery approach has advanced to clinical trials.

Under a Defense Advanced Research Projects Agency (DARPA) and Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) funded program, a novel COVID-19 antibody delivery approach has advanced to clinical trials.

Oral antiviral COVID-19 medications are available at just a handful of pharmacies across Pennsylvania.

During a Tuesday discussion hosted by the Pennsylvania Department of Health, doctors stressed one message: Get the COVID-19 vaccination.

Trial for Efficacy), evaluating INO-4800, its DNA vaccine candidate for COVID-19. Preliminary results show in a larger population that INO-4800 was generally safe, well-tolerated and immunogenic in all studied age groups. Findings from the Phase 2 Clinical Trial: The Phase 2 segment of the trial enrolled approximately 400 participants, 18 years of age or older, at 16 U.S. sites. Participants received either INO-4800 (1.0 mg or 2.0 mg dose) or placebo at 0 and 4 weeks (randomized 3:3:1:1). Eac...

Dr. J. Joseph Kim, President and Chief Executive Officer of INOVIO, said, "INOVIOs partnership with Advaccine enables us to leverage their deep expertise, capabilities and network across the region – making it possible to rapidly produce and if and when approved, distribute our vaccine candidate to more people across Greater China. This agreement also provides INOVIO with an Asian manufacturing partner with a near-term focus on INO-4800 and a long-term manufacturing resource potentially for o...

PLYMOUTH MEETING, Pa., Dec. 24, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases

Search jobs 24-Dec-2020 INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancets EClinicalMedicine PLYMOUTH MEETING, Pa., Dec. 24, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the publication of peer-reviewed Phase 1 clinical data from...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. DARPA and JPEO-CBRND Award $37.6M to The Wistar Institute and Collaborators at INOVIO, ... The Wistar InstituteDecember 15, 2020 GMT PHILADELPHIA, Dec. 15, 2020 (GLOBE NEWSWIRE) -- A team of scientists from The Wistar Institute, INOVIO, AstraZeneca, the Perelman School of Medicine at the University of Pennsylvania, and Indiana University has received a $37.6 million award over two years from the Def...